Evidence map›Paper›PMID 35852417›Full record

ReviewCancer discovery2022

Biomolecular Condensation: A New Phase in Cancer Research.

Anupam K Chakravarty, Daniel J McGrail, Thomas M Lozanoski, Brandon S Dunn, David J H Shih, Kara M Cirillo, Sueda H Cetinkaya, Wenjin Jim Zheng, Gordon B Mills, S Stephen Yi and 2 more

Open access · bronzeAbstract readReview
In one paragraph

Review in Cancer discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Protein-RNA condensation kinetics via filamentous nanoclusters.Protein science : a publication of the Protein Society · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Protein phase separation: new insights into cell division.Acta biochimica et biophysica Sinica · 2023
    Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 1 country.

Anupam K Chakravarty *Department of Molecular, Cellular, and Developmental Biology, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-4806-6741
Daniel J McGrail *Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, Ohio.ORCID 0000-0002-6669-6069
Thomas M LozanoskiDepartment of Bioengineering, Stanford University, Stanford, California.ORCID 0000-0002-5659-7032
Brandon S DunnDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-4374-0968
David J H ShihSchool of Biomedical Informatics, University of Texas Health Science Center at Houston, Houston, Texas.ORCID 0000-0002-9802-4937
Kara M CirilloDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-9040-0352
Sueda H CetinkayaDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Wenjin Jim ZhengSchool of Biomedical Informatics, University of Texas Health Science Center at Houston, Houston, Texas.ORCID 0000-0003-0252-1347
Gordon B MillsDepartment of Cell, Developmental and Cancer Biology, Knight Cancer Institute, Oregon Health and Sciences University, Portland, Oregon.ORCID 0000-0002-0144-9614
S Stephen YiDepartment of Oncology, Livestrong Cancer Institutes, The University of Texas at Austin, Austin, Texas.ORCID 0000-0003-0047-8103
Daniel F JaroszDepartment of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, California.ORCID 0000-0003-3497-5888
Nidhi SahniDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-9155-5882
The University of Texas MD Anderson Cancer Center · USThe University of Texas Health Science Center at Houston · USCleveland Clinic · USLivestrong Foundation · USOregon Health & Science University · USStanford Medicine · USStanford University · USUniversity of Michigan · US

Funding

Convalescent Plasma to Limit Coronavirus Associated ComplicationsUL1TR003167 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KARP, DANIEL D, MCPHERSON, DAVID D · 2019 to 2023
$45.3M
U.T. M. D. Anderson Cancer Center SPORE in Ovarian CancerP50CA217685 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MILLS, GORDON B. · 2017 to 2021
$7.9M
Integrative bioinformatics and functional characterization of oncogenic driver aberrations in cancerU01CA217842 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DENEEN, BENJAMIN, MILLS, GORDON B. · 2017 to 2021
$3.6M
Network-based Framework to Decode Novel Gain-of-Function Mutations and their Mechanistic Roles in General Human DiseasesR35GM133658 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI S. Stephen Yi · 2019 to 2026
$2.6M
Protein-based Molecular Memories in Gene Regulation, Disease, and DevelopmentDP2GM119140 · NIGMS · STANFORD UNIVERSITY · PI JAROSZ, DANIEL · 2015 to 2015
$2.4M
Deciphering Functional Consequences of Specific and Combinatorial Mutations in Protein Interaction NetworksR35GM137836 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SAHNI, NIDHI · 2020 to 2023
$1.8M
Determining the Immunological Consequences of DNA Replication Stress Response Defects in Renal Cells Carcinoma to Improve Immunotherapy OutcomesK99CA240689 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MCGRAIL, DANIEL JAMES · 2019 to 2020
$207k
Epigenetics in the extreme - investigating heritability driven by disordered RNA binding proteins in development and cancerK99GM128180 · NIGMS · STANFORD UNIVERSITY · PI CHAKRAVARTY, ANUPAM KUMAR · 2018 to 2019
$180k
Howard Hughes Medical Institute DRG2221-15NCATS NIH HHS UL1 TR003167NCI NIH HHS K99 CA240689NCI NIH HHS P50 CA217685NCI NIH HHS U01 CA217842NIGMS NIH HHS DP2 GM119140NIGMS NIH HHS K99 GM128180NIGMS NIH HHS R35 GM133658NIGMS NIH HHS R35 GM137836
6 · The paper itself

Abstract

Multicellularity was a watershed development in evolution. However, it also meant that individual cells could escape regulatory mechanisms that restrict proliferation at a severe cost to the organism: cancer. From the standpoint of cellular organization, evolutionary complexity scales to organize different molecules within the intracellular milieu. The recent realization that many biomolecules can "phase-separate" into membraneless organelles, reorganizing cellular biochemistry in space and time, has led to an explosion of research activity in this area. In this review, we explore mechanistic connections between phase separation and cancer-associated processes and emerging examples of how these become deranged in malignancy. SIGNIFICANCE: One of the fundamental functions of phase separation is to rapidly and dynamically respond to environmental perturbations. Importantly, these changes often lead to alterations in cancer-relevant pathways and processes. This review covers recent advances in the field, including emerging principles and mechanisms of phase separation in cancer.

Indexed as

NeoplasmsOrganellesHumansResearch

Identifiers

PMID35852417
PMCPMC9437557
OpenAlexW4286221663

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.